Home Computer Science Computational Diffusion MRI: MICCAI Workshop, Athens, Greece, October 2016
After the cingulum is implicated in many aspects of early PD manifestations including attention deficit, verbal and episodic memory impairment and depression which can also emerge as late consequences of PD . Results of our study showed that SWEDD and control group shared similar diffusion metric parameters which were significantly different from those with Parkinson disease (Table 2). As demonstrated by a previous study  the baseline severity of parkinsonian symptoms was lower in SWEDD group compared to PD group (T-test P-value=0.03). Meanwhile the H & Y stage of PD patients and SWEDD group were not statistically different (T-test P- value=0.55), both implicating minimal unilateral motor involvement. The MOCA score demonstrates absence of any detectable cognitive decline in any of the three groups. In fact all patients were enrolled from drug-naive recently diagnosed PD and SWEDD patients of the PPMI database whose PD or SWEDD status had been confirmed by DAT SCAN. This difference in microstructural changes of cingulum in PD and SWEDD group is in line with the absence of cognitive decline and nonmotor symptoms of any kind in SWEDD group. The difference in microstructural parameter of Cingulum can be considered as novel biomarker for early differential diagnosis of SWEDD from PD patients. The preponderance of GFA association but not the QA of cingulum might suggest that nondegenerative processes not involving axonal loss can better define or determine specific structural changes of PD vs. SWEDD group in newly diagnosed patients.
Acknowledgements This work was funded by grants from the Michael J Fox Foundation for Parkinson’s Research, the W Garfield Weston Foundation, and the Alzheimer’s Association, the Canadian Institutes for Health Research, and the Natural Sciences and Engineering Research Council of Canada. We thank Christian Beckmann and Simon Eickhoff for their advice on data analysis. Data used in this article were obtained from the Parkinsons Progression Markers Initiative (PPMI) database (www.ppmi-info.org/data). For up-to-date information on the study, visit www. ppmi-info.org. PPMI is sponsored and partially funded by the Michael J Fox Foundation for Parkinsons Research and funding partners, including AbbVie, Avid Radiopharmaceuticals, Biogen, Bristol-Myers Squibb, Covance, GE Healthcare, Genentech, GlaxoSmithKline (GSK), Eli Lilly and Company, Lundbeck, Merck, Meso Scale Discovery (MSD), Pfizer, Piramal Imaging, Roche, Servier, and UCB (www.ppmi-info.org/fundingpartners).
|< Prev||CONTENTS||Next >|